Pulmonary arteriovenous malformation

Jump to: navigation, search

WikiDoc Resources for Pulmonary arteriovenous malformation

Articles

Most recent articles on Pulmonary arteriovenous malformation

Most cited articles on Pulmonary arteriovenous malformation

Review articles on Pulmonary arteriovenous malformation

Articles on Pulmonary arteriovenous malformation in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pulmonary arteriovenous malformation

Images of Pulmonary arteriovenous malformation

Photos of Pulmonary arteriovenous malformation

Podcasts & MP3s on Pulmonary arteriovenous malformation

Videos on Pulmonary arteriovenous malformation

Evidence Based Medicine

Cochrane Collaboration on Pulmonary arteriovenous malformation

Bandolier on Pulmonary arteriovenous malformation

TRIP on Pulmonary arteriovenous malformation

Clinical Trials

Ongoing Trials on Pulmonary arteriovenous malformation at Clinical Trials.gov

Trial results on Pulmonary arteriovenous malformation

Clinical Trials on Pulmonary arteriovenous malformation at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pulmonary arteriovenous malformation

NICE Guidance on Pulmonary arteriovenous malformation

NHS PRODIGY Guidance

FDA on Pulmonary arteriovenous malformation

CDC on Pulmonary arteriovenous malformation

Books

Books on Pulmonary arteriovenous malformation

News

Pulmonary arteriovenous malformation in the news

Be alerted to news on Pulmonary arteriovenous malformation

News trends on Pulmonary arteriovenous malformation

Commentary

Blogs on Pulmonary arteriovenous malformation

Definitions

Definitions of Pulmonary arteriovenous malformation

Patient Resources / Community

Patient resources on Pulmonary arteriovenous malformation

Discussion groups on Pulmonary arteriovenous malformation

Patient Handouts on Pulmonary arteriovenous malformation

Directions to Hospitals Treating Pulmonary arteriovenous malformation

Risk calculators and risk factors for Pulmonary arteriovenous malformation

Healthcare Provider Resources

Symptoms of Pulmonary arteriovenous malformation

Causes & Risk Factors for Pulmonary arteriovenous malformation

Diagnostic studies for Pulmonary arteriovenous malformation

Treatment of Pulmonary arteriovenous malformation

Continuing Medical Education (CME)

CME Programs on Pulmonary arteriovenous malformation

International

Pulmonary arteriovenous malformation en Espanol

Pulmonary arteriovenous malformation en Francais

Business

Pulmonary arteriovenous malformation in the Marketplace

Patents on Pulmonary arteriovenous malformation

Experimental / Informatics

List of terms related to Pulmonary arteriovenous malformation

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

A pulmonary arteriovenous malformation (PAVM) is an abnormal connection between a branch of a pulmonary artery and a pulmonary vein through a thin-walled aneurysmal sac. PAVMs are most commonly congenital in nature and have a strong relationship with the syndrome of hereditary hemorrhagic telangiectasia (HHT). PAMVs act as direct right-to-left shunts and result in dyspnea, fatigue, cyanosis, and/or polycythemia when the shunt is large. Because the PAVM bypasses the capillary bed, the lung loses its filter function, and, thus, paradoxical emboli and bacteria are able to pass directly into the systemic circulation, with the result being or cerebral abscess. Selective embolization is the first-line procedure for the treatment of these malformations and leads to immediate occlusion of the PAVM in 90%–100% of cases and to continued occlusion 1 year after the procedure in more than 80% of cases.


WikiDoc Resources for Pulmonary arteriovenous malformation

Articles

Most recent articles on Pulmonary arteriovenous malformation

Most cited articles on Pulmonary arteriovenous malformation

Review articles on Pulmonary arteriovenous malformation

Articles on Pulmonary arteriovenous malformation in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pulmonary arteriovenous malformation

Images of Pulmonary arteriovenous malformation

Photos of Pulmonary arteriovenous malformation

Podcasts & MP3s on Pulmonary arteriovenous malformation

Videos on Pulmonary arteriovenous malformation

Evidence Based Medicine

Cochrane Collaboration on Pulmonary arteriovenous malformation

Bandolier on Pulmonary arteriovenous malformation

TRIP on Pulmonary arteriovenous malformation

Clinical Trials

Ongoing Trials on Pulmonary arteriovenous malformation at Clinical Trials.gov

Trial results on Pulmonary arteriovenous malformation

Clinical Trials on Pulmonary arteriovenous malformation at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pulmonary arteriovenous malformation

NICE Guidance on Pulmonary arteriovenous malformation

NHS PRODIGY Guidance

FDA on Pulmonary arteriovenous malformation

CDC on Pulmonary arteriovenous malformation

Books

Books on Pulmonary arteriovenous malformation

News

Pulmonary arteriovenous malformation in the news

Be alerted to news on Pulmonary arteriovenous malformation

News trends on Pulmonary arteriovenous malformation

Commentary

Blogs on Pulmonary arteriovenous malformation

Definitions

Definitions of Pulmonary arteriovenous malformation

Patient Resources / Community

Patient resources on Pulmonary arteriovenous malformation

Discussion groups on Pulmonary arteriovenous malformation

Patient Handouts on Pulmonary arteriovenous malformation

Directions to Hospitals Treating Pulmonary arteriovenous malformation

Risk calculators and risk factors for Pulmonary arteriovenous malformation

Healthcare Provider Resources

Symptoms of Pulmonary arteriovenous malformation

Causes & Risk Factors for Pulmonary arteriovenous malformation

Diagnostic studies for Pulmonary arteriovenous malformation

Treatment of Pulmonary arteriovenous malformation

Continuing Medical Education (CME)

CME Programs on Pulmonary arteriovenous malformation

International

Pulmonary arteriovenous malformation en Espanol

Pulmonary arteriovenous malformation en Francais

Business

Pulmonary arteriovenous malformation in the Marketplace

Patents on Pulmonary arteriovenous malformation

Experimental / Informatics

List of terms related to Pulmonary arteriovenous malformation

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Associate Editor(s)-in-Chief: Your Name

Synonyms and Keywords: Synonym 1; Synonym 2; Synonym 3

Overview

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

  • [Disease name] may be caused by either [cause1], [cause2], or [cause3].
  • [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
  • There are no established causes for [disease name].

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected with [disease name] than [gender 2].
  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease name].
  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
  • Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action 1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

Gallery

References



Linked-in.jpg